Skip to main content
. 2021 May 3;29:100363. doi: 10.1016/j.jbo.2021.100363

Fig. 4.

Fig. 4

Kaplan-Meier survival estimates to compare patients with de novo BoM versus those with asynchronous metastases. A.) Median overall survival for patients with de novo BoM was 58.3 months (95% CI: 34.9, 118.8), while median survival for patients with asynchronous BoM was 139.7 months (95% CI: 110.1, 212.6). B.) Median BoM survival for de novo patients was 58.3 months (95% CI: 33.9, 116.7), and 42.9 months (95% CI: 35, 55.6) for those with asynchronous metastases.